TC Biopharm (Holdings) Plc (TCBP)

TC Biopharm (Holdings) Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for TCBP.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for TCBP.

Recommendation Trends

Rating	Jan '23	Feb '23	Mar '23	Apr '23
Strong Buy	2	2	2	0
Buy	0	0	0	0
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	2	2	2	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $18,000 → $14,000	Strong Buy	Maintains	$18,000 → $14,000	+2,222,122.22%	Apr 27, 2023
Mitchell Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $18,000	Strong Buy	Initiates	$18,000	+2,857,042.86%	Jan 26, 2023
Constantine Davides EF Hutton	EF Hutton	Strong Buy Initiates $500,000	Strong Buy	Initiates	$500,000	+79,364,979.37%	Mar 28, 2022

More Analyst Ratings

Financial Forecast

• Revenue This Year:
  n/a
• Revenue Next Year:
  n/a
• EPS This Year:
  n/a
• EPS Next Year:
  n/a

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023
Revenue	3.43M	1.98M	1.98M	3.84M	-
Revenue Growth	-	-42.26%	-	94.30%	-
EPS	-	-	-	-	-191.21
EPS Growth	-	-	-	-	-
Forward PE	-	-	-	-	-
No. Analysts	-	-	-	-	-

Financial currency is GBP. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue
High
Avg
Low

Revenue Growth

Revenue Growth
High
Avg
Low

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.